The present invention relates to the use of low molecular weight (lmw) compounds, especially lmw compounds with GPR4-affinity, in the treatment of diseases and disorders which includes gastroesophageal reflux disease (GERD), and/or non-erosive reflux disease (NERD) and the like.
[EN] IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS IMIDAZOPYRIDINE COMME MODULATEURS DU RÉCEPTEUR GPR4
申请人:NOVARTIS AG
公开号:WO2009144201A1
公开(公告)日:2009-12-03
The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.